PMID- 19440008
OWN - NLM
STAT- MEDLINE
DCOM- 20090717
LR  - 20220316
IS  - 1423-0399 (Electronic)
IS  - 0042-1138 (Linking)
VI  - 82
IP  - 3
DP  - 2009
TI  - Impact of surgical and medical castration on serum testosterone level in prostate 
      cancer patients.
PG  - 249-55
LID - 10.1159/000209352 [doi]
AB  - INTRODUCTION: The paper aims at evaluating the role of testosterone levels and 
      their cut-off points in the treatment of prostate cancer with androgen 
      deprivation therapy. MATERIALS AND METHODS: We performed a non-systematic review 
      of the literature, searching Medline using the following key words: 'Prostatic 
      neoplasms/therapy' [MeSH], 'Buserelin' [MeSH], 'Goserelin' [MeSH], 'Leuprolide' 
      [MeSH], 'Triptorelin' [MeSH], 'prostate cancer*' [tiab], and 'testoster*' [tiab]. 
      RESULTS: The most commonly used cut-off point of testosterone to define 
      castration was 50 ng/dl. In this respect, GnRH agonists allowed castration in a 
      very high percentage of patients (87.5-100%). Specifically, triptorelin was 
      reported to yield castration level of testosterone in 98.8%, the classical 
      formulation of leuprolide in 95-98.8% of the cases, and Eligard, a novel 
      formulation of leuprolide, in 99-100%. With regard to the 20-ng/dl breakpoint, 
      available data suggest that goserelin yields castration level of testosterone in 
      96%, the classical formulation of leuprolide in 87-92% of the patients, and the 
      novel formulation in 88-97.5%. CONCLUSIONS: The clinical significance of 
      different levels of testosterone yielded during androgen deprivation therapy is 
      still unknown. Considering the standard cut-off point of 50 ng/dl, GnRH agonists 
      allowed castration in a very high percentage of patients.
CI  - Copyright 2009 S. Karger AG, Basel.
FAU - Novara, Giacomo
AU  - Novara G
AD  - IRCCS Istituto Oncologico Veneto (IOV), University of Padua, Padua, Italy. 
      giacomonovara@gmail.com
FAU - Galfano, Antonio
AU  - Galfano A
FAU - Secco, Silvia
AU  - Secco S
FAU - Ficarra, Vincenzo
AU  - Ficarra V
FAU - Artibani, Walter
AU  - Artibani W
LA  - eng
PT  - Journal Article
PT  - Review
PT  - Systematic Review
DEP - 20090511
PL  - Switzerland
TA  - Urol Int
JT  - Urologia internationalis
JID - 0417373
RN  - 0 (Androgen Antagonists)
RN  - 0 (Antineoplastic Agents, Hormonal)
RN  - 0 (Biomarkers)
RN  - 33515-09-2 (Gonadotropin-Releasing Hormone)
RN  - 3XMK78S47O (Testosterone)
SB  - IM
MH  - Androgen Antagonists/*therapeutic use
MH  - Antineoplastic Agents, Hormonal/*therapeutic use
MH  - Biomarkers/blood
MH  - Drug Monitoring
MH  - Gonadotropin-Releasing Hormone/*agonists
MH  - Humans
MH  - Male
MH  - *Orchiectomy
MH  - Prostatic Neoplasms/blood/drug therapy/surgery/*therapy
MH  - Testosterone/*blood
MH  - Treatment Outcome
RF  - 38
EDAT- 2009/05/15 09:00
MHDA- 2009/07/18 09:00
CRDT- 2009/05/15 09:00
PHST- 2008/07/18 00:00 [received]
PHST- 2008/11/05 00:00 [accepted]
PHST- 2009/05/15 09:00 [entrez]
PHST- 2009/05/15 09:00 [pubmed]
PHST- 2009/07/18 09:00 [medline]
AID - 000209352 [pii]
AID - 10.1159/000209352 [doi]
PST - ppublish
SO  - Urol Int. 2009;82(3):249-55. doi: 10.1159/000209352. Epub 2009 May 11.